Tuberculosis during TNF-α inhibitor therapy, despite screening.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 23598710.
- Also identified by DOI 10.1136/thoraxjnl-2012-202974.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
As part of a prospective study on the safety of TNF-α inhibitor therapy after screening for and treatment of latent tuberculosis infection (LTBI), we report two patients who developed active tuberculosis (TB) infection during TNF-α inhibitor therapy, despite negative screening for LTBI. The clinical history is suggestive of a primary infection acquired during travelling to TB-endemic countries. In this lesson of the month we would like to highlight the risk of travelling to TB-endemic areas in patients treated with TNF-α inhibitor therapy. Screening for latent tuberculosis infection is not enough to prevent tuberculosis in patients treated with TNF-α inhibitor therapy.
Medical subject headings
- Antibodies, Monoclonal
- Immunocompromised Host
- Inflammatory Bowel Diseases
- Latent Tuberculosis
- Tuberculosis, Pulmonary
- Tumor Necrosis Factor-alpha